NG2 Stock Chart & Stats
€8.03
€0.30(2.46%)
At close: 4:00 PM EST
€8.03
€0.30(2.46%)
Day’s Range― - ―
52-Week Range€4.00 - €9.80
Previous CloseN/A
Volume0.00
Average Volume (3M)91.00
Market Cap
€1.89B
Enterprise Value€3.08K
Total Cash (Recent Filing)€159.90M
Total Debt (Recent Filing)€793.30M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Jul 30, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.80
Shares Outstanding217,673,030
10 Day Avg. Volume54
30 Day Avg. Volume91
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.61
Price to Sales (P/S)1.42
P/FCF Ratio-27.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.52Price Target Upside31.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.26
Revenue Forecast (FY)€746.38M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables-driven RevenueNeogen’s core business sells consumable test kits and reagents used in routine safety workflows, creating repeatable demand tied to production volume and regulation. This recurring consumables model supports steady unit demand, predictable refill revenue and durable cash generation versus one-time sales.
Food Safety Segment Growth And Product StrengthConsistent core growth in Food Safety, led by high-growth indicator and pathogen kits, signals product-market fit and sticky customer adoption. Because Food Safety is driven by regulatory and quality spend, segment momentum supports margin sustainability and recurring consumable demand over the medium term.
Improving Cash Flow And Planned Divestiture To Cut LeveragePositive free cash flow combined with a planned $160M genomics divestiture provides a credible path to materially reduce net leverage. Improved cash generation and lower debt should increase financial flexibility to fund Petrifilm ramp, targeted R&D and transformation investments over the coming 6–12 months.
Bears Say
Severely Deteriorated ProfitabilityTrailing profitability has collapsed to deeply negative net margins, eroding retained earnings and ROE. Sustained losses impair the company’s ability to self-fund restructuring and R&D, increase reliance on debt or asset sales, and raise execution risk for multi-year transformation plans.
Animal Safety Supply And Margin DisruptionThird-party supplier failures caused material revenue decline and negative sample collection margins. Persistent supplier quality and sourcing issues threaten recurring service revenues and customer confidence in Animal Safety, making margin recovery and sustained growth in that segment uncertain.
Elevated Leverage And Weak ReturnsAlthough leverage has modestly improved, gross debt remains large versus cash and profitability is negative, producing very weak ROE. This constrains strategic optionality, raises refinancing and covenant risk if losses persist, and limits ability to invest ahead of the Petrifilm ramp until balance sheet repair is complete.
Neogen News
NG2 FAQ
What was Neogen Corp’s price range in the past 12 months?
Neogen Corp lowest stock price was €4.00 and its highest was €9.80 in the past 12 months.
What is Neogen Corp’s market cap?
Neogen Corp’s market cap is €1.89B.
When is Neogen Corp’s upcoming earnings report date?
Neogen Corp’s upcoming earnings report date is Jul 30, 2026 which is in 7 days.
How were Neogen Corp’s earnings last quarter?
Neogen Corp released its earnings results on Apr 09, 2026. The company reported €0.079 earnings per share for the quarter, beating the consensus estimate of €0.051 by €0.028.
Is Neogen Corp overvalued?
According to Wall Street analysts Neogen Corp’s price is currently Undervalued.
Does Neogen Corp pay dividends?
Neogen Corp does not currently pay dividends.
What is Neogen Corp’s EPS estimate?
Neogen Corp’s EPS estimate is 0.05.
How many shares outstanding does Neogen Corp have?
Neogen Corp has 217,673,030 shares outstanding.
What happened to Neogen Corp’s price movement after its last earnings report?
Neogen Corp reported an EPS of €0.079 in its last earnings report, beating expectations of €0.051. Following the earnings report the stock price went up 2.865%.
Which hedge fund is a major shareholder of Neogen Corp?
Currently, no hedge funds are holding shares in DE:NG2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.52 (31.07% Upside)
€10.52 (31.07% Upside)
Blogger Sentiment
Bullish
DE:NG2 Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.78%
Trailing 12-Months
Company Description
Neogen Corp
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.
NG2 Stock 12 Month Forecast
Average Price Target
€10.52
▲(31.07% Upside)











